Can I read Immunoglobulin Repletion During Blinatumomab Therapy Does Not Reduce the Rate of Secondary Hypogammaglobulinemia and Associated Infectious Risk on EtoBox?

Immunoglobulin Repletion During Blinatumomab Therapy Does Not Reduce the Rate of Secondary Hypogammaglobulinemia and Associated Infectious Risk by Stephanie Wo; Hannah Levavi; John Mascarenhas; Marina Kremyanskaya; Shyamala Navada; Michal Bar-Natan; Sara S. Kim is a Medicine article available to read on EtoBox.

What is Immunoglobulin Repletion During Blinatumomab Therapy Does Not Reduce the Rate of Secondary Hypogammaglobulinemia and Associated Infectious Risk about?

## Background Blinatumomab has demonstrated efficacy in minimal residual disease (MRD) positive and relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) by inciting rapid and sustained B-cell depletion. ## Methods Owing to its effect on B-cells, blinatumomab is associated with a higher rate of secondary hypogammaglobulinemia compared to chemotherapy. To mitigate blinatumomab-induced hypogammaglobulinemia, patients were pre-emptively repleted with intravenous immune globulin (IVIG) during blinatumomab therapy. In this retrospective study, we compared outcomes of 23 blinatumomab treated adults with ALL. Seventeen patients routinely received IVIG and 6 patients were in the control cohort. ## Results Our findings demonstrated no difference between the two cohorts in immunoglobulin G (IgG) nadir (338 mg/dL vs. 337 mg/dL, __P__=0.641), days to IgG nadir (120.5 vs. 85.5 days, __P__=0.13), infection rate (82.4% vs. 66.7%, __P__=0.58), infections requiring ICU admission (23.5% vs. 16.7%, __P__=1), and infection related mortality (17.6% vs. 16.7%, __P__=1). ## Conclusion Pre-emptive IVIG repletion during blinatumomab did not prevent hypogammaglo-bulinemia and associated infection

Who reads Immunoglobulin Repletion During Blinatumomab Therapy Does Not Reduce the Rate of Secondary Hypogammaglobulinemia and Associated Infectious Risk?

Author

Stephanie Wo; Hannah Levavi; John Mascarenhas; Marina Kremyanskaya; Shyamala Navada; Michal Bar-Natan; Sara S. Kim

Published

2022

Language

EN

Field

Medicine (Health Sciences)